Prices delayed by at least 15 minutes | Print
Allergy Therapeutics PLC (AGY)
ORD 0.1PThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Company profile
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Address
Dominion Way
Worthing
West Sussex
GBR
BN14 8SA
Telephone
+44 1903844700
Forecast key dates
| Name | Key Date |
|---|---|
| Allergy Therapeutics PLC Fourth Quarter Earnings Results for 2026 | 2026-12-11T00:00:00 |
| Allergy Therapeutics PLC Annual Report for 2026 | 2026-12-11T00:00:00 |
| Allergy Therapeutics PLC Second Quarter Earnings Results for 2026 | 2026-03-31T00:00:00 |
| Allergy Therapeutics PLC Annual General Meeting for 2025 | 2025-12-29T00:00:00 |
| Allergy Therapeutics PLC Annual Report for 2025 | 2025-12-11T00:00:00 |
| Allergy Therapeutics PLC Fourth Quarter Earnings Results for 2025 | 2025-12-11T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Allergy Therapeutics PLC Annual General Meeting for 2025 | 2025-12-29T00:00:00 |
| Allergy Therapeutics PLC Annual Report for 2025 | 2025-12-11T00:00:00 |
| Allergy Therapeutics PLC Fourth Quarter Earnings Results for 2025 | 2025-12-11T00:00:00 |
| Allergy Therapeutics PLC Second Quarter Earnings Results for 2025 | 2025-03-31T00:00:00 |
| Allergy Therapeutics PLC Annual General Meeting for 2024 | 2024-12-16T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.